Day: August 2, 2021

Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals (“Eledon”) (NASDAQ: ELDN), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today announced that it plans to release financial results for the second quarter ended June 30, 2021 on Thursday, August 12, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 pm ET. Conference Call and Webcast Details:Thursday, August 12, 2021 at 4:30 PM Eastern Time / 1:30 PM Pacific TimeToll Free: 877-407-9039 International: 201-689-8470 Conference ID: 13720793Webcast: https://ir.eledon.com/events-and-presentations/events After...

Suominen Corporation’s press release on August 2, 2021 at 3:00. p.m. (EEST) Suominen Corporation will publish its Interim report for January 1 – June 30, 2021 on Friday, August 13, 2021 at approximately 9:30 a.m. (EEST). Petri Helsky, President & CEO, and Toni Tamminen, CFO, will present the result in English in an audiocast and a conference call for analyst, investors and media on the same day at 11:00 a.m. (EEST). The audiocast can be followed at https://suominen.videosync.fi/2021-q2-results. The recording of the audiocast and the presentation material will be available after the event at www.suominen.fi. Conference call participants are requested to dial on:Sweden: +46 856642651 United Kingdom: +44 3333000804 United States: +1 6319131422  The confirmation code for joining the conference call is 21713834#. The event cannot be attended...

DUBLIN, Ireland and TREVOSE, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (“Strongbridge”), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced for the purposes of the Irish Takeover Panel Act, 1997, Takeover Rules 2013 (the “Irish Takeover Rules”), that the definitive joint proxy statement/prospectus of Strongbridge (the “Proxy Statement”), which also constitutes a scheme circular under Irish law, is being sent as of July 30, 2021 to Strongbridge shareholders. As previously announced on May 24, 2021, Xeris Pharmaceuticals, Inc. (“Xeris”) and Strongbridge entered into a definitive transaction agreement pursuant to which Xeris will acquire Strongbridge in a stock and CVR...

Achieved performance milestone with positive initial results from its Phase 1b trial of CERC-002 in moderate-to- severe Crohn’s Disease who had previously failed three or more lines of biologics therapies, including anti-TNF alpha treatments ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced that it has completed its second drawdown of $10 million under its previously announced $35 million debt financing agreement with Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon”). This second tranche was made available in connection with the Company’s successful positive initial results from...

Total GAAP revenue increased 43.0% year-over-year to $59.4 millionAnnual recurring revenue increased 42.4% year-over-year to $240.6 millionTotal number of customers reached over 41,000Cash flow from operations was $14.1 million and free cash flow was $12.8 millionTAMPA BAY, Fla., Aug. 02, 2021 (GLOBE NEWSWIRE) —  KnowBe4, Inc. (NASDAQ: KNBE), provider of the leading security awareness training and simulated phishing platform, today reported results for the second quarter ended June 30, 2021. “Our second quarter results exceeded our expectations across the board with record annual recurring revenue (ARR) of $241 million and total customers of over 41,000,” said Stu Sjouwerman, founder and chief executive officer of KnowBe4. “We are excited about the extremely positive response to the release of our newest product, Compliance...

Proceeds will fund continued development of IMVT-1401 in multiple indicationsNEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has received a $200 million strategic investment from Roivant Sciences. Immunovant intends to use the proceeds from this investment to advance the development of IMVT-1401 in multiple indications. Roivant has purchased 17,021,276 shares of Immunovant’s common stock at a price of $11.75 per share, which purchase has been approved by a special committee of Immunovant directors not affiliated with Roivant. This represents approximately a 15% premium to Immunovant’s 20 trading day volume weighted average price. After giving effect to the investment,...

NEW YORK and SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced that the first patient has been dosed in the Phase 2 trial of ZN-c3, the Company’s oral WEE1 inhibitor product candidate, in adult women with recurrent or persistent uterine serous carcinoma (USC). Following an end-of-Phase 1 meeting, the U.S. Food and Drug Administration agreed in principle that ZN-c3 has the potential for an accelerated approval pathway based on the Phase 2 global study design in USC. “This trial, with its potential accelerated approval pathway, underscores our potential ability to efficiently develop and advance promising therapeutic...

Pivotal Trial Builds on Results from FORTITUDE-ALS which Demonstrated Slowing of Declineof SVC and ALSFRS-R in Patients on Reldesemtiv Compared to Placebo Company Is Planning to Provide Continued Access to Patients Who Complete COURAGE-ALS and Patients Who Previously Participated in Cytokinetics Sponsored ALS Trials SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that COURAGE-ALS (Clinical Outcomes Using Reldesemtiv on ALSFRS-R in a Global Evaluation in ALS), a Phase 3 clinical trial of reldesemtiv in patients with amyotrophic lateral sclerosis (ALS), is open to enrollment. Reldesemtiv, a next-generation fast skeletal muscle troponin activator (FSTA) arising from Cytokinetics’ skeletal muscle contractility program, slows the rate of calcium release from the...